Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
OCHNCNP-1 by EA Pharma for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
OCHNCNP-1 is under clinical development by EA Pharma and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS). According...
Data Insights
OCHNCNP-1 by EA Pharma for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
OCHNCNP-1 is under clinical development by EA Pharma and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS). According...